Nanalysis Scientific ( (TSE:NSCI) ) has issued an announcement.
Nanalysis Scientific Corp. reported a record quarterly adjusted EBITDA of at least $1 million and positive free cash flow for Q4 2024, driven by increased revenue from its Benchtop NMR product line and expansion in airport security services. The company also highlighted a co-published study with the United States Pharmacopeia, demonstrating the efficacy of its Benchtop NMR for quality control in pharmaceuticals, which could enhance its market positioning in the pharma/biotech sector. Additionally, the company achieved significant revenue growth in its security services business, with improvements in gross margins, aligning with its corporate objectives of generating positive EBITDA and cash flow.
More about Nanalysis Scientific
Nanalysis Scientific Corp. is a leader in portable NMR instruments and imaging technology, providing services for industrial and research applications. The company focuses on the Benchtop NMR product line and airport security services, aiming to enhance its market position through innovation and strategic growth.
YTD Price Performance: -7.27%
Average Trading Volume: 53,672
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $23.28M
Learn more about NSCI stock on TipRanks’ Stock Analysis page.